IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc.

27.21
EUR
-0.57
(-2.05%)
-3.98EPS
3.30BMarket Cap
Feb 23Next Earn

Total Valuation

EUR

As of September 30, 2026, IDEAYA Biosciences, Inc. carries a market capitalization of 3.30B, placing it among publicly traded companies globally. Its enterprise value stands at 2.59B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.30B
Enterprise Value2.59B

Important Dates

IDEAYA Biosciences, Inc.'s next confirmed earnings release is scheduled for February 23, 2027.

Earnings Date2/23/2027

Share Statistics

As of September 30, 2026, IDEAYA Biosciences, Inc. has 96.65M shares outstanding.

Shares Outstanding96.65M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 98.63, and the price-to-book ratio stands at 3.43.

PS Ratio98.63
PB Ratio3.43
P/TBV Ratio3.43
P/FCF Ratio-10.30
P/OCF Ratio-10.37

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 80.28 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.59B versus a market cap of 3.30B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales80.28

Financial Position

As of September 30, 2026, IDEAYA Biosciences, Inc. maintains a current ratio of 9.04, meaning it holds 9.0x the short-term assets needed to cover near-term liabilities.

Current Ratio9.04
Quick Ratio8.80
Debt / Equity2.72
Debt / EBITDA-0.06

Financial Efficiency

EUR

Over the twelve months ended September 30, 2026, IDEAYA Biosciences, Inc. posted a negative return on equity (ROE) of -38.46, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -34.98, reflecting losses generated across the asset base. The company generates approximately 222,309.18 in revenue per employee across its workforce of 145.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-38.46
Return on Assets (ROA)-34.98
Revenue Per Employee222,309.18
Employee Count145.00

Stock Price Statistics

EUR

As of the close on November 17, 2026, IDEAYA Biosciences, Inc.'s stock has declined approximately 5.52% over the past 52 weeks. The 50-day moving average sits at 31.15, while the 200-day moving average is 29.44.

52-Week Price Change-5.52%
50-Day Moving Average31.15
200-Day Moving Average29.44

Income Statement

EUR

Over the twelve months ended September 30, 2026, IDEAYA Biosciences, Inc. generated 32.23M in revenue and converted that into -370.58M in net income, yielding earnings per share of -3.98. EBITDA reached -404.57M, while operating income came in at -408.54M.

Revenue32.23M
Operating Income-408.54M
Pretax Income-370.58M
Net Income-370.58M
EBITDA-404.57M
EBIT-408.54M
Earnings Per Share (EPS)-3.98

Balance Sheet

EUR

As of September 30, 2026, IDEAYA Biosciences, Inc. holds 739.84M in cash and equivalents against 26.21M in total debt, resulting in a net debt position of -230.68M. Total book value stands at 963.53M, with working capital of 684.28M providing operational flexibility.

Cash & Cash Equivalents739.84M
Total Debt26.21M
Net Debt-230.68M
Equity (Book Value)963.53M
Book Value Per Share9.97
Working Capital684.28M

Cash Flow

EUR

IDEAYA Biosciences, Inc. produced -306.47M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -2.15M in capital expenditures, free cash flow totaled -308.63M - equivalent to -3.32 per share.

Operating Cash Flow-306.47M
Capital Expenditures-2.15M
Free Cash Flow-308.63M
FCF Per Share-3.32

Margins

These figures cover the twelve months ended September 30, 2026. The operating margin of -1,267.38 and net profit margin of -1,149.62 provide insight into operational efficiency.

Operating Margin-1,267.38
Pretax Margin-1,149.62
Profit Margin-1,149.62
EBITDA Margin-1,255.08

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -9.71: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.79, meaning IDEAYA Biosciences, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-9.79
FCF Yield-9.71

Scores

As of September 30, 2026, IDEAYA Biosciences, Inc. has an Altman Z-Score of 16.42, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score16.42